Cwm LLC Decreases Stake in Medpace Holdings, Inc. $MEDP

Cwm LLC lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 6,927 shares of the company’s stock after selling 1,220 shares during the period. Cwm LLC’s holdings in Medpace were worth $2,174,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group increased its holdings in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after acquiring an additional 71 shares during the last quarter. Whittier Trust Co. increased its holdings in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the last quarter. IFP Advisors Inc increased its holdings in Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in Medpace in the 1st quarter worth about $60,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several analyst reports. William Blair restated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and raised their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. TD Cowen restated a “sell” rating and issued a $366.00 target price (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Robert W. Baird raised their target price on Medpace from $313.00 to $490.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research note on Tuesday, September 9th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $430.60.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares in the company, valued at $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $2,725,380. The trade was a 66.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock worth $74,111,427. Company insiders own 20.30% of the company’s stock.

Medpace Trading Up 1.3%

Shares of MEDP opened at $528.07 on Friday. The company has a market cap of $14.84 billion, a PE ratio of 39.26, a price-to-earnings-growth ratio of 3.31 and a beta of 1.40. The stock has a 50-day moving average price of $492.23 and a 200-day moving average price of $382.32. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the company posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.